MENU

Industry uses of human pluripotent stem cells

Speaker
  • Senior Scientist, Amgen
    Biography
      Stuart Chambers received his Ph.D. from Baylor College of Medicine in the lab of Margaret A Goodell in studying hematopoietic stem cell biology and gene therapy. His postdoctoral work was conducted in the lab of Lorenz Studer identifying methods to neuralize pluripotent stem cells for the purposes of creating neurons for use in cell therapy and induced pluripotent stem cell disease modeling. His cell therapy work was continued as a Scientist when he joined start-up company Neurona Therapeutics. He now works at Amgen as a Senior Scientist in Discovery Research within the Genome Analysis Unit and is tasked with using pluripotent stem cell derived cell fates for target identification, human disease modeling, and drug development.

    Abstract

    Human pluripotent stem cells (hPSCs) and their derivatives are increasingly being used in industry to gain a competitive edge in drug discovery and a new wave of biotechnology start-up companies are poised to evaluate hPSC-derived cell therapies.  Over the past decade protocols to a broad repertoire of hPSC-derived cell fates have been identified and published differentiating pluripotent stem cells to generate cells more capable of recapitulating phenotypes seen in primary cells.  Although, commercial uses for these cells are quite similar to academics on the day-to-day, there are stark differences in how industry plans to use pluripotent tissue.  Seen through the lens of industry, approaches to high throughput screening, how one employs disease modeling, and the overall need for greater scale and reproducibility become greater priorities.

    Worldwide hPSC-derived cells are being evaluated in clinical trials, and with great enthusiasm within the United States several industry and academic efforts are underway to determine if a cure can be found.  These endeavors further underscore the importance of keeping the technical limitations of hPSCs and their derivatives in mind.  Numerous hurdles still remain before cells can make it to the clinic.  Cells will have to be thoroughly vetted for safety, engineering solutions need to be identified for large-scale production, and protocols require adaptation to adhere to good manufacturing practices.  Even then, limitations remain as to appropriate disease indications for cellular therapies.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    JUN 03, 2021 12:00 PM CST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    JUN 03, 2021 12:00 PM CST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...

    Industry uses of human pluripotent stem cells


    Specialty

    Genetics

    Dna Sequencing

    Clinical Oncology

    Cancer Therapeutics

    Biotechnology

    Oncology

    Genomics

    Gene Sequencing

    Clinical Research

    Cell Biology

    Pcr/rt-Pcr/real-Time Pcr

    Cancer Diagnostics

    Bioinformatics

    Immunology

    Gene Therapy

    Geography

    North America60%

    Asia20%

    Europe20%

    Registration Source

    Website Visitors100%

    Job Title

    Research Scientist33%

    Pharmacist11%

    Student11%

    Executive11%

    Educator/Faculty11%

    Biologist11%

    Scientist11%

    Organization

    Research Institute20%

    Academic Institution10%

    Medical School10%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more